This also significantly hampers any opportunity to resect tumours in these models; however, with the advent of mutant Kras inhibitors and the use of optimal radiotherapy regimens, local tumour control could provide a window of opportunity for testing systemic targeted therapies. This evidence concerns the gene KRAS and neoplasm.